ALK Positive Australia is pleased to share an important outcome regarding our recent advocacy work with the Pharmaceutical Benefits Advisory Committee (PBAC).
The PBAC has recommended that alectinib be made available on the PBS for people diagnosed with early-stage ALK-positive lung cancer following surgery. This is a significant step forward. It means more patients will have access to a highly effective targeted treatment earlier in their cancer journey.
Importantly, the PBAC also specifically acknowledged the contribution of ALK Positive Australia in its decision making process. This is not something they do often, and it highlights the strength and credibility of our community voice.
They noted the concerns we raised around fairness, access to treatment, and the importance of allowing patients to continue receiving targeted therapies if their cancer returns. This shows that your experiences, your stories, and your voices are being heard at the highest levels..
This is exactly why ALK Positive Australia exists.
We are stronger together.
As individuals, it is difficult to influence national decisions like this. But as a united community, we are able to advocate effectively, bring forward real patient experiences, and help shape policy that impacts all of us.
Advocacy is a core part of our Strategic Plan, and as our organisation continues to grow, so too does our ability to improve access, equity, and outcomes for people living with ALK-positive lung cancer across Australia.
Thank you for being part of this community and for helping make this progress possible. If you are not a member of ALK Positive Australia please do join us, as we truly are stronger together.